[go: up one dir, main page]

MX2019007067A - Inhibidores de azepano de la interacción menina-mll. - Google Patents

Inhibidores de azepano de la interacción menina-mll.

Info

Publication number
MX2019007067A
MX2019007067A MX2019007067A MX2019007067A MX2019007067A MX 2019007067 A MX2019007067 A MX 2019007067A MX 2019007067 A MX2019007067 A MX 2019007067A MX 2019007067 A MX2019007067 A MX 2019007067A MX 2019007067 A MX2019007067 A MX 2019007067A
Authority
MX
Mexico
Prior art keywords
menin
inhibitors
azepane
mll interaction
compounds
Prior art date
Application number
MX2019007067A
Other languages
English (en)
Other versions
MX391405B (es
Inventor
René Angibaud Patrick
Noëlle Constance Pilatte Isabelle
Alexis Georges Querolle Olivier
Pande Vineet
Herkert Barbara
Jason Krosky Daniel
Nathaniel Patrick Aaron
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2017/082826 external-priority patent/WO2018109088A1/en
Publication of MX2019007067A publication Critical patent/MX2019007067A/es
Publication of MX391405B publication Critical patent/MX391405B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se relaciona con agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero y, en particular, con compuestos de azepam, la composición farmacéutica que comprende tales compuestos, y su uso como inhibidores de la interacción menina/MLL proteína/proteína, útiles para tratar enfermedades tales como cáncer, síndrome mielodisplástico (MDS, pos sus siglas en inglés) y diabetes.(ver formula).
MX2019007067A 2016-12-15 2017-12-14 Inhibidores de azepano de la interacción menina-mll. MX391405B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662434549P 2016-12-15 2016-12-15
EP17150502 2017-01-06
PCT/EP2017/082826 WO2018109088A1 (en) 2016-12-15 2017-12-14 Azepane inhibitors of menin-mll interaction

Publications (2)

Publication Number Publication Date
MX2019007067A true MX2019007067A (es) 2019-10-15
MX391405B MX391405B (es) 2025-03-21

Family

ID=60935807

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007067A MX391405B (es) 2016-12-15 2017-12-14 Inhibidores de azepano de la interacción menina-mll.

Country Status (11)

Country Link
US (2) US10745409B2 (es)
EP (1) EP3555103B1 (es)
JP (1) JP7142010B2 (es)
KR (1) KR102513564B1 (es)
CN (1) CN110248946B (es)
AU (1) AU2017376599B2 (es)
BR (1) BR112019012106A2 (es)
CA (1) CA3044739A1 (es)
ES (1) ES2901227T3 (es)
IL (1) IL267277B (es)
MX (1) MX391405B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20220154A1 (ar) 2019-12-19 2023-01-30 Janssen Pharmaceutica Nv مشتقات سبيرو بسلسلة مستقيمة بها استبدال
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
CN116693546B (zh) * 2022-01-28 2025-06-27 成都先导药物开发股份有限公司 Menin抑制剂及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
PL372145A1 (en) 2002-02-19 2005-07-11 Cv Therapeutics, Inc. Partial and full agonists of a sb 1 /sb adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US20040138238A1 (en) * 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
CA2509406C (en) 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
EP1753428A4 (en) 2004-05-14 2010-09-15 Abbott Lab INHIBITORS OF KINASES AS THERAPEUTIC AGENTS
AU2006206738A1 (en) 2005-01-19 2006-07-27 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
JP5343975B2 (ja) 2008-10-06 2013-11-13 日本電気株式会社 無線通信装置、無線通信システム、無線通信装置の制御方法、及びプログラム
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
EP2473054B1 (en) * 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
EP2646454B1 (en) 2010-12-03 2015-07-08 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2011341441A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
EP2620094B1 (en) 2011-08-01 2015-10-14 Olympus Corporation Apparatus for displaying shape of insertion portion
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN103664991B (zh) 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
WO2014100730A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
WO2014100695A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
US9216993B2 (en) * 2013-03-13 2015-12-22 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2015191701A1 (en) * 2014-06-10 2015-12-17 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US10246464B2 (en) 2014-09-09 2019-04-02 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016081732A1 (en) * 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
CN108779116A (zh) 2015-12-22 2018-11-09 生命医药公司 多发性内分泌瘤蛋白-mll相互作用的抑制剂
SMT202300273T1 (it) 2016-03-16 2023-09-06 Kura Oncology Inc Derivati di tieno[2,3–d]pirimidina sostituiti come inibitori di menina–mll e metodi d’uso
MA43823A (fr) 2016-03-16 2018-11-28 Kura Oncology Inc Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
SG11201809714TA (en) 2016-05-02 2018-11-29 Univ Michigan Regents Piperidines as menin inhibitors
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
KR20250079083A (ko) 2016-06-10 2025-06-04 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
KR102339881B1 (ko) 2016-09-06 2021-12-14 가부시끼가이샤 쓰리본드 열경화형 도전성 접착제
CN109689663B (zh) 2016-09-14 2023-04-14 詹森药业有限公司 Menin-mll相互作用的螺二环抑制剂
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
MX2019003091A (es) 2016-09-16 2019-07-08 Vitae Pharmaceuticals Inc Inhibidores de la interaccion de menina-mll.
EA201990699A1 (ru) 2016-10-05 2019-09-30 Янссен Фармацевтика Нв Спиробициклические ингибиторы взаимодействия менин–mll
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
CN117298275A (zh) 2017-03-24 2023-12-29 库拉肿瘤学公司 治疗血液系统恶性肿瘤和尤因肉瘤的方法

Also Published As

Publication number Publication date
US20200339594A1 (en) 2020-10-29
US10745409B2 (en) 2020-08-18
US11530226B2 (en) 2022-12-20
CA3044739A1 (en) 2018-06-21
AU2017376599A1 (en) 2019-08-01
KR102513564B1 (ko) 2023-03-22
CN110248946B (zh) 2023-05-23
MX391405B (es) 2025-03-21
IL267277A (en) 2019-08-29
US20190322685A1 (en) 2019-10-24
BR112019012106A2 (pt) 2019-10-29
IL267277B (en) 2022-04-01
CN110248946A (zh) 2019-09-17
KR20190092518A (ko) 2019-08-07
EP3555103A1 (en) 2019-10-23
AU2017376599B2 (en) 2021-10-07
JP2020512290A (ja) 2020-04-23
ES2901227T3 (es) 2022-03-21
JP7142010B2 (ja) 2022-09-26
EP3555103B1 (en) 2021-09-22

Similar Documents

Publication Publication Date Title
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CR20160271A (es) Compuestos peptidométicos y sus conjugados de anticuerpo-fármaco
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CO2017002268A2 (es) Inhibidores espirocíclicos de catepsina c
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
CL2013003160A1 (es) Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros.
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
TR201908265T4 (tr) Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.
MX2017013571A (es) Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap).
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX380314B (es) Citotoxinas modificadas y su uso terapeutico.
MX2019007067A (es) Inhibidores de azepano de la interacción menina-mll.
CL2015000886A1 (es) Compuestos derivados de azaindolinas sustituidas, inhibidores de la union de proteinas smac al inhibidor de proteinas de apoptosis (iap) y/o inhibidores de la union de proteina caspasa activada a los iap; composicion farmaceutica que los comprende; metodo para tratar o mejorar un cancer; y su uso para el tratamiento terapeutico y/o profilactico del cancer.
MX2023013176A (es) Derivados espiro sustituidos.